Maze Therapeutics Inc. (MAZE)
Market Open
19 Oct, 01:50 PM
NASDAQ (NMS) NASDAQ (NMS) Primary $
27. 85
+0.32
+1.1624%
$
1.53B Market Cap
- P/E Ratio
- Div Yield
2,999 Volume
- Eps
$ 27.53
Previous Close 
Want to track MAZE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
Reuters | 1 year ago
Maze Therapeutics Seeks IPO For Trials Ramp-Up
Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidney disease, with promising Phase 1 results. Maze has strong financial backing and a significant partnership with Shionogi & Co., positioning it well for future development.
Seekingalpha | 1 year ago
2026 © Marketlog. All Rights Reserved.
